biomea fusion

02/17/2024

Spreading joy one cookie at a time! Our office celebrated Valentine's Day with a cookie decorating activity that brought out everyone's inner artist. Take a peek at the fun we had! 🎨🍪

01/26/2024

✨ Exciting times at last week! Our dedicated team member, Nicole Kowalczyk, proudly shared insights from our groundbreaking work through an engaging poster presentation.

01/11/2024

Concluding another successful J.P. Morgan meeting in San Francisco. Presenting at JPM was an honor, and the meetings turned out to be exceptionally productive!

01/10/2024

We're thrilled to be a part of the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco! 🚀 View our presentation at: https://investors.biomeafusion.com/news-events/events



📸: Thomas Butler, Juan Pablo Frias, Ramses Erdtmann

01/10/2024

📣 Thomas Butler, Biomea Fusion's Chief Executive Officer and Chairman of the Board, will present recent clinical progress and 2024 corporate milestones at the 42nd Annual J.P. Morgan Healthcare Conference. Read more: https://investors.biomeafusion.com/news-releases/news-release-details/biomea-fusion-highlights-recent-updates-and-anticipated-2024

Expansion portion of Phase II COVALENT-111 study readout in 216 patients with type 2 diabetes expected in 2024. Open label portion of Phase II COVALENT-112 study readout in 40 patients with type 1 diabetes expected in 2024. REDWOOD CITY, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc.

12/29/2023

Wrapping up 2023 with Biomea Fusion’s biggest diabetes program moments of this year. From data and regulatory milestones to congresses, team events and more. Click through to see some of our 2023 . Thank you to all our teams and partners who helped make it happen. Here’s to 2024! 🎉

12/18/2023

Biotech TV came by our Innovation Lab and met with Biomea Fusion CEO Tom Butler to discuss our covalent menin inhibitor program in diabetes and oncology and our recent data presented at and .
Watch a preview video here 👉 https://x.com/BiotechTVHQ/status/1736749788425838705?s=20
Watch the full video here 👉 https://www.biotechtv.com/post/biomea-fusion-december-18-2023

12/14/2023

🎯 We are thrilled to be named as one of seven companies shaping the future of precision medicine by .eu. Read the article here: https://www.labiotech.eu/best-biotech/precision-medicine-companies/

Explore the forefront of healthcare innovation with these seven cutting-edge biopharma companies specializing in precision medicine.

12/11/2023

📣 Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH
Read more here: https://investors.biomeafusion.com/news-releases/news-release-details/biomea-fusion-presents-achievement-minimal-residual-disease

12/11/2023

📣 Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH
Read more here: https://investors.biomeafusion.com/news-releases/news-release-details/biomea-fusion-presents-achievement-minimal-residual-disease

BMF-219 demonstrated early signs of clinical activity and ability to achieve durable and sustained complete responses (CRs) with minimal residual disease negativity (MRD-neg) in acute myeloid leukemia (AML) patients Pharmacodynamic data further supports the mechanism of action of BMF-219 as a menin

12/11/2023

📢HAPPENING NOW: Biomea Fusion poster presentation tonight until 8:00pm PST at . Our Chief Development Officer Steve Morris shares the highlights of our COVALENT-101 study. See you there!
➡️Poster: 2916

12/11/2023

Our is making a splash at ! Visit us at our booth #3223 and learn about our 🧪